Article citationsMore>>
Manning, H.C., Merchant, N.B., Foutch, A.C., Virostko, J.M., Wyatt, S.K., Shah, C., McKinley, E.T., Xie, J., Mutic, N.J., Washington, M.K., LaFleur, B., Tantawy, M.N., Peterson, T.E., Ansari, M.S., Baldwin, R.M., Rothenberg, M.L., Bornhop, D.J., Gore, J.C. and Coffey, R.J. (2008) Molecular Imaging of Therapeutic Response to Epidermal Growth Factor Receptor Blockade in Colorectal Cancer. Clinical Cancer Research, 14, 7413-7422.
http://dx.doi.org/10.1158/1078-0432.CCR-08-0239
has been cited by the following article:
-
TITLE:
Preclinical Evaluation of CD40-Directed Immunotherapy in B-Cell Lymphoma Using [18F]Fluorothymidine-PET
AUTHORS:
Nicolas Graf, Zhoulei Li, Ken Herrmann, Michaela Aichler, Jolanta Slawska, Axel Walch, Christian Peschel, Markus Schwaiger, Andreas K. Buck, Tobias Dechow, Ulrich Keller
KEYWORDS:
CD40 Antibody, FLT-PET, Lymphoma, Therapy Monitoring
JOURNAL NAME:
Advances in Molecular Imaging,
Vol.5 No.2,
April
9,
2015
ABSTRACT: Background: Inhibition of the lymphoma surface antigen CD40 by the
antagonistic CD40 antibody NVP-HCD122 (HCD122) demonstrates activity in various
lymphoma subtypes. In this preclinical in
vivo study we examined the suitability of positron emission tomography
(PET) using the thymidine analogue 3’-deoxy-3’-[18F]fluorothymidine
(FLT) for early response assessment upon HCD122 treatment in diffuse large B
cell lymphoma (DLBCL). Methods: Immunodeficient mice bearing human DLBCL
xenografts (SU-DHL-4) received weekly intraperitoneal injections of HCD122.
Tumor growth was followed up until Day 14. Molecular imaging with FLT-PET was
performed before (Day 0) and after start of therapy (Day 2 and Day 7). On Day 14
lymphoma xenografts were explanted for immunohistochemical analysis to correlate
PET findings with CD40 surface expression on tumor tissue. Results: Treatment
with HCD122 significantly delayed tumor growth resulting in a tumor growth
inhibition of 45% on Day 14. Significant reduction of tumor-to-background ratio
(TBR) of FLT-PET was seen in treated animals on Day 7 and preceded change of
tumor volume, thus predicting therapy response to HCD122. Immunohistochemical
analysis of xenografts revealed significantly higher CD40 expression on treated
than on untreated tissue. Moreover, we found a significant correlation between
CD40 expression and FLT-PET response for xenograft tumor treated with HCD122. Conclusions:
Treatment of DLBCL with the antagonistic CD40 antibody HCD122 can be monitored
with FLT-PET as early as seven days after commencement of therapy and seems to
increase CD40 expression on tumor tissue.
Related Articles:
-
Elisée Hategekimana, Déogratias Ruhangaza, Christian Hansen, Emile Musoni, Belson Rugwizangoga, Kelsey Hammel, Rosen Daniel Gustavo, Djibril Mbarushimana, Theoneste Nizeyimana, Theogene Twagirumugabe, Jules Ndoli, Felicité Mukamana, Christian Ngarambe, Emmanuel Habimana, Callie Weber
-
Lamiae Amaadour, Soumia Berrad, Ibtissam El Harch, Karima Oualla, Samia Arifi, Karima El Ghazi, Laila Chbani, Zineb Benbrahim, Nawfel Mellas
-
Elrasheid A. H. Kheirelseid, Nicola Miller, Michael J. Kerin
-
Amira Daldoul, Olfa Gharbi, Laila Ben Fatma, Imene Chabchoub, Sonia Zaied, Khaled Ben Ahmed, Faten Ezzairi, Makrem Hochlef, Imtinene Belaid, Sami Limem, Slim Ben Ahmed
-
May El Sherif, Claus Peter Schneider, Carola Rabenstein, Amina Hessein Hassab, Magdy Mamdouh El Bordiny, Mona Wagdy Ayad, Katharina Pachmann